Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Cerilliant
US Army
Mallinckrodt
Colorcon
Express Scripts
Deloitte
Argus Health
Fish and Richardson

Generated: September 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,770,623

« Back to Dashboard

Which drugs does patent 6,770,623 protect, and when does it expire?

Patent 6,770,623 protects FORTEO and is included in one NDA.

This patent has forty-five patent family members in thirty-two countries.

Summary for Patent: 6,770,623
Title: Stabilized teriparatide solutions
Abstract:A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol or benzyl alcohol as a preservative.
Inventor(s): Chang; Chin-Ming (Fishers, IN), Havel; Henry A. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/555,476
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,770,623
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Composition; Use; Dosage form;

Drugs Protected by US Patent 6,770,623

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y A METHOD OF TREATING OSTEOPOROSIS ➤ Sign Up
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Sign Up ➤ Sign Up Y FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,770,623

PCT Information
PCT FiledDecember 08, 1998PCT Application Number:PCT/US98/26043
PCT Publication Date:June 17, 1999PCT Publication Number: WO99/29337

International Family Members for US Patent 6,770,623

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 018526 ➤ Sign Up
Austria 260113 ➤ Sign Up
Australia 1717799 ➤ Sign Up
Australia 759726 ➤ Sign Up
Brazil 9813463 ➤ Sign Up
Canada 2314313 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Chinese Patent Office
Healthtrust
Covington
Accenture
Cerilliant
US Department of Justice
Argus Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.